BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3864924)

  • 1. Carbohydrate antigen (CA 19-9)--a valuable tumor marker of pancreatic cancer.
    Lin JT; Wang TH; Sung JL; Chen DS
    Taiwan Yi Xue Hui Za Zhi; 1985 Jul; 84(7):828-35. PubMed ID: 3864924
    [No Abstract]   [Full Text] [Related]  

  • 2. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
    Klapdor R; Greten H
    Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
    [No Abstract]   [Full Text] [Related]  

  • 3. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer.
    Pasquali C; Sperti C; D'Andrea AA; Bonadimani B; Del Favero G; Petrin P; Pedrazzoli S
    Pancreas; 1987; 2(1):34-7. PubMed ID: 3472197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of the carbohydrate antigen CA-50 in pancreatic disease.
    Blind PJ; Dahlgren ST
    Acta Chir Scand; 1987 Jan; 153(1):45-9. PubMed ID: 3472420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic importance of the tumor marker CA 19-9 in pancreatic cancer].
    Safi F; Büchler M; Schenkluhn B; Beger HG
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1869-73. PubMed ID: 6209082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of a serum pancreatic tumor marker: the carbohydrate antigen C.A. 19-9].
    Vincent D; Venot J; Catanzano G; Clément MN; Piquet MF; Veyriras E; Beck C
    Ann Med Interne (Paris); 1985; 136(2):142-4. PubMed ID: 3865571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The contribution of CA 19-9 in the differential diagnosis between chronic pancreatitis and cancer of the pancreas].
    Van Gossum M; Delanghe A; Gerard M; Delcourt A; Deltenre M
    Acta Gastroenterol Belg; 1987; 50(1):91-4. PubMed ID: 3480672
    [No Abstract]   [Full Text] [Related]  

  • 9. [Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases].
    Heptner G; Domschke S; Schneider MU; Domschke W
    Dtsch Med Wochenschr; 1985 Apr; 110(16):624-8. PubMed ID: 3857159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
    Staab HJ
    Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
    [No Abstract]   [Full Text] [Related]  

  • 11. [Significance of the determination of serum CA19.9 in patients with tumor or non-tumor pancreatopathies].
    Encabo G; Ruibal A; Gefaell R; Martínez Miralles E; Salgado A; Fernández Llamazares J
    Med Clin (Barc); 1984 Mar; 82(12):560-1. PubMed ID: 6588282
    [No Abstract]   [Full Text] [Related]  

  • 12. [Attention to CA 19.9 in alcoholics. Apropos of a case].
    Giovannini M; Penalvert F; Maillot A; Escoffier JM; Botta D; Gauthier A
    Ann Gastroenterol Hepatol (Paris); 1987 Dec; 23(7):393. PubMed ID: 3481241
    [No Abstract]   [Full Text] [Related]  

  • 13. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Farini R; Fabris C; Bonvicini P; Piccoli A; del Favero G; Venturini R; Panucci A; Naccarato R
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):429-32. PubMed ID: 3859414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pancreatic oncofetal antigen (POA)].
    Mugitani H; Furue H; Kako M; Hirota F; Fuse K; Takahashi T; Sakamoto K; Yamada K; Suminaga M; Ezaki M; Judo R
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1737-43. PubMed ID: 6882002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CA 19-9, a new tumor marker].
    Akai S
    Rinsho Byori; 1983 Dec; 31(12):1300-2. PubMed ID: 6587136
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of new three tumor markers for pancreatic carcinoma: CA19/9, CA 125 and DuPan 2].
    Ohkura H; Sakawaki T
    Gan No Rinsho; 1985 May; 31(6 Suppl):583-8. PubMed ID: 3861882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
    Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
    Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma].
    Röthlin M; Metzger U; Joller H; Largiadèr F
    Schweiz Med Wochenschr; 1988 Jun; 118(24):924-9. PubMed ID: 2456610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
    Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
    Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA 19-9 and pancreatic adenocarcinoma.
    Safi F; Beger HG; Bittner R; Büchler M; Krautzberger W
    Cancer; 1986 Feb; 57(4):779-83. PubMed ID: 3455839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.